PDA

View Full Version : AEZS (MC $67 M) (Cash $45.7M ) FDA Decision on Nov 5= 300% Potential !



DaveLandry
07-04-2014,
This Stock is one of the cheapest in the Biotech Sector . They have $45.7 M in Cash and a Market Cap of just $67 M thats ridiculous for a Company with such a Mega Pipeline .Another good sign is that Management bought 187k Shares in last few weeks .This is the Perfect time to load up before the speculators jumping in .

FDA decision on November 5 (Macrilen) and Interim Phase 3 results in 1H 2015 (ZoptEC) !

AEZS could run to $3-5 before FDA decision in early November .GL


Aeterna Zentaris (AEZS)

Market Cap: $67 M
Cash: $45.7 M
Price: $1.18

Shares Out: 56.5 M


Insider activity:
http://canadianinsider.com/node/7?menu_tickersearch=aez

Jun 10/14 Jun 10/14 Egbert, Carolyn Direct Ownership Common Shares 10 - Acquisition in the public market 100,000 $1.10 USD

Apr 14/14 Apr 11/14 Dodd, David Alan Direct Ownership Common Shares 10 - Acquisition in the public market 87,000 $1.15 USD


Pipeline
http://www.aezsinc.com/en/page.php?p=20


New Presentation
http://www.aezsinc.com/pdfdyn/AEZS presentation June 2014.pdf



MACRILEN?(macimorelin)

?Filing of a New Drug Application ("NDA") seeking approval for the commercialization of MACRILEN? as the firstavailable oral product indicated for the evaluation of Adult Growth Hormone Deficiency


. NDA currently undersubstantive review by the US Food and Drug
Administration with a Prescription Drug User Fee Act date of November 5,2014


Zoptarelin doxorubicin

Operate trial in support of achieving first interim analysis for
ZoptEC Phase 3 trial in H1-2015